Evotec SE — Form 20-F summary
Reporting period: Fiscal year ended December 31, 2022. This is an annual report, not a standalone fourth-quarter filing; quarterly results are not clearly provided in the filing text. Financial statements are prepared under IFRS and presented in euros. The report was signed May 10, 2023.
Business context
Evotec is a drug discovery, development and manufacturing partner serving pharmaceutical and biotechnology companies. Its two segments are EVT Execute, principally fee-for-service and FTE work, and EVT Innovate, comprising internal R&D and partnerships involving Evotec-owned or co-owned intellectual property. At year-end, the company reported 4,952 employees, 819 customers, and 18 disclosed pipeline assets in clinical development, alongside more than 120 discovery- and preclinical-stage assets.
Financial results and liquidity
| Metric | 2022 | 2021 | Change / context |
|---|---|---|---|
| Revenue | €751.4 million | €618.0 million | Up 21.6%; growth was primarily from fee-for-service and FTE revenue. |
| Gross profit / gross margin | €174.1 million / 23.2% | €151.5 million / 24.5% | Margin declined; excluding Just-Evotec Biologics capacity build-up effects, management reported 30.8% versus 28.4%. |
| Operating income | €20.9 million | €41.0 million | Lower amid higher SG&A and operating costs. |
| Net income (loss) | €(175.7) million | €215.5 million | Primarily reflects a reversal in investment fair-value results, including a significant decline in Exscientia’s share price. |
| Adjusted EBITDA | €101.7 million | €107.3 million | Down 5.2%; this is a non-IFRS measure. |
| Operating cash flow | €203.1 million | €122.2 million | Includes a substantial BMS prepayment for an expanded collaboration. |
| Investing / financing cash flow | €(415.8) million / €(52.4) million | €(243.9) million / €398.4 million | Investing outflows included €181.4 million of property, plant and equipment purchases; 2021 financing benefited from the U.S. ADS offering. |
| Cash and cash equivalents; current investments | €415.2 million; €303.3 million | €699.3 million; €158.9 million | Combined cash, cash equivalents and current investments were €718.5 million at year-end 2022. |
| Loan liabilities; lease liabilities | €329.9 million; €176.8 million | €362.5 million; €150.4 million | Management’s net-cash measure, which deducts loans and lease obligations from cash and cash equivalents, was negative €91.5 million. |
Revenue from service fees and FTE-based research payments rose to €642.4 million, while milestone and license revenue fell to €20.5 million from €49.7 million. The filing’s narrative separately describes milestone and license payments of €18.1 million and notes that royalties began following South Korean approval of SKY Covione; figures vary by revenue classification, so investors should check the detailed disclosures.
Material changes versus 2021
- Revenue increased 21.6%, driven by service and FTE work; the three largest customers represented 25% of revenue in both years. Repeat business increased to 92% from 91%.
- Gross margin fell to 23.2% from 24.5%, with ramp-up costs at the Redmond biologics facility, inflation and higher energy costs among the cited pressures.
- SG&A rose 48% to €156.2 million, reflecting headcount growth, U.S.-listing and SOX-compliance costs, consulting, insurance and IT spending.
- The investment measurement result swung from a €223.8 million gain in 2021 to a €172.2 million loss in 2022. The filing attributes a €174.7 million fair-value decrease to Exscientia, primarily following its share-price decline.
- Unpartnered R&D spending increased 20.8% to €70.2 million. The company acquired Rigenerand, adding cell and gene therapy manufacturing capabilities, and Central Glass Germany, now Evotec Drug Substance.
Outlook, risks and unusual items
- Management expects fee-for-service and FTE revenue to grow at a mid-to-high single-digit rate in the near term. Its longer-term strategy targets more than 170 pipeline assets by the end of 2025 and expects royalties to become more meaningful by then; these are forward-looking goals, not guarantees.
- Planned 2023 capital expenditure includes €120–125 million for replacement and growth, plus identified investments in Redmond, Toulouse and other facilities. The filing also describes planned J.POD expansion spending separately; the precise aggregate commitment should be verified against the detailed capital plan.
- Evotec reported €150 million of EIB financing secured in December 2022, available in tranches during 2023–2025; none had been drawn at year-end. Existing loan agreements were reported in compliance with covenants.
- In April 2023, after the reporting period, Evotec suffered a ransomware attack that disrupted operations and affected IT systems. The company reported data encryption and exfiltration, preliminary access to some employee and customer-related information, and an ongoing investigation. It could not yet quantify costs or insurance recoveries and warned of potential effects on 2023 performance.
- Management and the auditor concluded that internal control over financial reporting was ineffective at December 31, 2022 because of material weaknesses, including insufficient technical accounting and supervisory resources, inconsistent processes, and deficiencies in IT access controls. The auditor nevertheless issued an unqualified opinion on the IFRS financial statements.
- Other disclosed risks include dependence on partners’ drug-development decisions, customer concentration, uncertain returns on equity investments, foreign-exchange and interest-rate exposure, supply and energy disruption, regulation, intellectual-property protection, and cybersecurity. The company reported no material litigation then pending.
Important facts for investors to verify
- Reconcile the reported €172.2 million investment measurement loss with the €174.7 million Exscientia fair-value decrease and other investment movements.
- Review the definition and reconciliation of Adjusted EBITDA, including the difference between €101.7 million reported for the year and €104.1 million referenced in the management bonus discussion.
- Assess how much 2022 operating cash flow depended on the BMS prepayment, and how that prepayment will be recognized as services are delivered.
- Track the remediation of internal-control weaknesses and the financial-reporting and operational consequences of the April 2023 cyber incident, including final costs, recoveries and any data-related liabilities.
- Test the funding needs, timelines, utilization and return assumptions for the Redmond and Toulouse J.POD facilities and the broader 2023 capital expenditure plan.
- Monitor partner-led clinical progress, pipeline partnering, milestone and royalty realization, and the sensitivity of investment valuations to market prices and future financing.